Sagimet is pharmaceutical company developing novel therapeutics to treat important diseases .Our lead product candidate TVB-2640 is an oral, highly potent, selective and reversible, first-in-class FASN inhibitor.
Location: United States, California, San Mateo
Employees: 11-50
Total raised: $105M
Founded date: 2006
Investors 4
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| - | Altium Cap... | altiumcap.... |
| - | PFM Health... | pfmhealths... |
| - | Pivotal Ca... | pivotalcp.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.02.2021 | - | $80M | - |
| 05.08.2019 | Series E | $25M | - |
Mentions in press and media 15
| Date | Title | Description |
| 29.01.2026 | Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne | - Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The exceptional efficacy of denifanstat (ASC40) observed in the Company's previo... |
| 10.12.2025 | Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment | -Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multice... |
| 14.10.2025 | Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration | - Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controll... |
| 18.09.2025 | Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereo... | --Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne compared with placebo. --Denifanstat (ASC40) demonstrated a favorable safety and tolerab... |
| 12.03.2025 | Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates | Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigational New Drug (IND) application for FASN I... |
| 23.01.2024 | Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH | Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis - Primary efficacy endpoints: NASH resolution without worsening o... |
| 22.01.2024 | Investigators fault Lilly plant for manufacturing issues | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, lots of regulatory content! We talk about march-in rights and chastening TikTok influencers for their prescri... |
| 18.08.2021 | HistoIndex's Stain-free AI-based Digital Pathology Incorporated as Secondary and Exploratory Efficacy Endpoints in Sagimet's NASH FASCINATE-2 Phase 2b Clinical Trial | SINGAPORE, Aug. 18, 2021 /PRNewswire/ -- HistoIndex, a global leading artificial intelligence (AI) digital pathology provider, has announced an agreement with clinical-stage biotechnology company Sagimet Biosciences. HistoIndex's integrated... |
| 16.03.2021 | Sagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug Administration for FASN Inhibitor TVB-2640 in NASH | |
| 12.02.2021 | Sagimet Biosciences Raises $80M in Crossover Financing | Sagimet Biosciences, a San Mateo, Calif.-based clinical-stage biotechnology company, raised $80m in crossover financing. The round was led by an undisclosed public equity healthcare investment fund with participation from existing investors... |
Show more